BioXcel Therapeutics, Inc.:
Clinical stage company utilizing AI technology platform to identify improved therapies in neuroscience and immuno-oncology. BXCL501 (sublingual dexmedetomidine): Met primary, key secondary and exploratory endpoints in two pivotal Phase 3 trials for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). NDA submission to FDA planned 1Q21; Phase 1b/2 trial (TRANQUILITY) ongoing for the acute treatment of agitation associated with geriatric dementia. Data expected 4Q20; BXCL701 (innate immunity activator): Phase 1b/2 ongoing of BXCL701 and KEYTRUDA for Prostate Cancer (tNEPC).
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - New England
Clinical Stage
Phase III, Phase l or ll
Disease Space
Central Nervous System, Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Platform Technology, Small Molecule
Website:
Address:
555 Long Wharf Drive
5th Floor
New Haven, Connecticut 06511
United States
5th Floor
New Haven, Connecticut 06511
United States
Presentation:
Company Participants at Solebury Trout Corporate Access 1x1 Calls - Week of April 13
- Vimal Mehta, Dr, CEO
More info:
My account:
Top 10 Holders of BioXcel Therapeutics, Inc.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| State Street Corp. | 5.40 | 974,381 | 45.33 | 13F | 6/30/20 |
| DNCA Finance SA | 3.99 | 892,453 | 41.52 | Stakes | 3/3/20 |
| Artemis Investment Management LLP | 3.89 | 701,498 | 32.63 | 13F | 6/30/20 |
| The Vanguard Group, Inc. | 3.72 | 674,432 | 31.37 | Funds | 9/30/20 |
| Vanguard Group, Inc. (Subfiler) | 3.01 | 543,381 | 25.28 | 13F | 6/30/20 |
| AllianceBernstein LP | 2.80 | 504,405 | 23.46 | 13F | 6/30/20 |
| Avidity Partners Management LP | 2.15 | 388,095 | 18.05 | 13F | 6/30/20 |
| BlackRock Fund Advisors | 2.02 | 364,425 | 16.95 | 13F | 6/30/20 |
| Acuta Capital Partners LLC | 1.89 | 340,500 | 15.84 | 13F | 6/30/20 |
| Citadel LP | 1.74 | 313,962 | 14.61 | 13F | 6/30/20 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.